XML 51 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Dec. 18, 2023
Nov. 11, 2022
Aug. 05, 2013
Dec. 27, 2023
Sep. 29, 2021
Dec. 18, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Average interest rate, short-term bank deposits in U.S. dollars             6.20% 4.84%  
Amortization in R&D expenses             $ 325 $ 6,019 $ 1,291
Revenue recognition under milestone method   $ 7,500   $ 10,000 $ 6,000 $ 2,000      
Severance expenses             432 $ 468 $ 383
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned     $ 10,000       10,000    
Research And Development Arrangement Payments Receivable     $ 250,000       200,000    
Accrued milestone payment             25,500    
License revenue             23,459    
Deferred revenues included in current liabilities             11,149    
Deferred revenues included in non current liabilities             $ 25,392    
Options [Member]                  
Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share             7,921,020 8,405,615 6,758,300
Master Clinical Agreement One [Member]                  
Investment amount             $ 12,000    
Deferred participation of BMS in R&D expenses             4,121    
Master Clinical Agreement Two [Member]                  
Investment amount             20,000    
Deferred participation of BMS in R&D expenses             $ 5,000    
License Agreement With Gilead [Member]                  
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned $ 60,000                
Research And Development Arrangement Payments Receivable $ 788,000